Irreversible Electroporation Plus Anti-PD-1 Antibody versus Irreversible Electroporation Alone for Patients with Locally Advanced Pancreatic Cancer

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Amin MB, Edge S, Greene F. AJCC Cancer Staging Manual. Chicago, IL: Springer; 2017.
   Google Scholar
• Weniger M, Moir J, Damm M, et al. Respect - a multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Pancreatology. 2020;20:1131–1138. doi:10.1016/j.pan.2020.06.012
   PubMed Web of Science ®Google Scholar
• Loehrer PJ, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29:4105–4112. doi:10.1200/JCO.2011.34.8904
   PubMed Web of Science ®Google Scholar
• Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315:1844–1853. doi:10.1001/jama.2016.4324
   PubMed Web of Science ®Google Scholar
• Girelli R, Frigerio I, Giardino A, et al. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg. 2013;398:63–69. doi:10.1007/s00423-012-1011-z
   PubMed Web of Science ®Google Scholar
• Pezzilli R, Ricci C, Serra C, et al. The problems of radiofrequency ablation as an approach for advanced unresectable ductal pancreatic carcinoma. Cancers (Basel). 2010;2:1419–1431. doi:10.3390/cancers2031419
   PubMedGoogle Scholar
• Al Efishat M, Wolfgang CL, Weiss MJ. Stage III pancreatic cancer and the role of irreversible electroporation. BMJ. 2015;350:h521. doi:10.1136/bmj.h521
   PubMedGoogle Scholar
• He C, Huang X, Zhang Y, Lin X, Li S. T-cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer. Clin Transl Med. 2020;10:e39. doi:10.1002/ctm2.39
   PubMed Web of Science ®Google Scholar
• He C, Sun S, Zhang Y, Xie F, Li S. The role of irreversible electroporation in promoting M1 macrophage polarization via regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer. Oncoimmunology. 2021;10:1897295. doi:10.1080/2162402X.2021.1897295
   PubMed Web of Science ®Google Scholar
• He C, Sun S, Zhang Y, Li S. Identification of circulating biomarkers and construction of a prognostic signature for survival prediction in locally advanced pancreatic cancer after irreversible electroporation. J Inflamm Res. 2021;14:1689–1699. doi:10.2147/JIR.S307884
   PubMed Web of Science ®Google Scholar
• Scheffer HJ, Stam AGM, Geboers B, et al. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation. Oncoimmunology. 2019;8:1652532. doi:10.1080/2162402X.2019.1652532
   PubMed Web of Science ®Google Scholar
• Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125:3384–3391. doi:10.1172/JCI80011
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454. doi:10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, Phase 2–3 study. Lancet Oncol. 2021;22:977–990. doi:10.1016/S1470-2045(21)00252-7
   PubMed Web of Science ®Google Scholar
• Torphy RJ, Zhu Y, Schulick RD. Immunotherapy for pancreatic cancer: barriers and breakthroughs. Ann Gastroenterol Surg. 2018;2:274–281. doi:10.1002/ags3.12176
   PubMed Web of Science ®Google Scholar
• Tsukamoto M, Imai K, Ishimoto T, et al. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Cancer Sci. 2019;110:310–320.
   PubMed Web of Science ®Google Scholar
• Henriksen A, Dyhl-Polk A, Chen I, Nielsen D. Checkpoint inhibitors in pancreatic cancer. Cancer Treat Rev. 2019;78:17–30. doi:10.1016/j.ctrv.2019.06.005
   PubMed Web of Science ®Google Scholar
• Yang J, Eresen A, Shangguan J, Ma Q, Yaghmai V, Zhang Z. Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer. Oncoimmunology. 2021;10:1875638. doi:10.1080/2162402X.2021.1875638
   PubMed Web of Science ®Google Scholar
• Zhao J, Wen X, Tian L, et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat Commun. 2019;10:899. doi:10.1038/s41467-019-08782-1
   PubMed Web of Science ®Google Scholar
• He C, Wang J, Zhang Y, Lin X, Li S. Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: a propensity score matching analysis. Pancreatology. 2020;20:477–484. doi:10.1016/j.pan.2020.02.009
   PubMed Web of Science ®Google Scholar
• He C, Sun S, Huang X, Zhang Y, Lin X, Li S. Survival comparison of neoadjuvant chemotherapy followed by irreversible electroporation versus conversional resection for locally advanced pancreatic cancer. Front Oncol. 2020;10:622318. doi:10.3389/fonc.2020.622318
   PubMed Web of Science ®Google Scholar
• He C, Wang J, Sun S, Zhang Y, Li S. Immunomodulatory effect after irreversible electroporation in patients with locally advanced pancreatic cancer. J Oncol. 2019;2019:9346017. doi:10.1155/2019/9346017
   PubMed Web of Science ®Google Scholar
• Crane CH, Varadhachary GR, Yordy JS, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011;29:3037–3043. doi:10.1200/JCO.2010.33.8038
   PubMed Web of Science ®Google Scholar
• Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5:1020–1027. doi:10.1001/jamaoncol.2019.0892
   PubMed Web of Science ®Google Scholar
• Beetz O, Sarisin A, Kaltenborn A, Klempnauer J, Winkler M, Grannas G. Multivisceral resection for adenocarcinoma of the pancreatic body and tail-a retrospective single-center analysis. World J Surg Oncol. 2020;18:218. doi:10.1186/s12957-020-01973-x
   PubMed Web of Science ®Google Scholar
• Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med. 2015;4:1171–1177. doi:10.1002/cam4.459
   PubMed Web of Science ®Google Scholar
• Martin RC, Kwon D, Chalikonda S, et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 2015;262:486. doi:10.1097/SLA.0000000000001441
   PubMed Web of Science ®Google Scholar
• He C, Huang X, Zhang Y, Cai Z, Lin X, Li S. Comparison of survival between irreversible electroporation followed by chemotherapy and chemotherapy alone for locally advanced pancreatic cancer. Front Oncol. 2020;10:6. doi:10.3389/fonc.2020.00006
   PubMed Web of Science ®Google Scholar
• Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol. 2008;19:1592–1599.
   PubMed Web of Science ®Google Scholar
• Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007;110:47–55. doi:10.1002/cncr.22735
   PubMed Web of Science ®Google Scholar
• Moir J, White SA, French JJ, Littler P, Manas DM. Systematic review of irreversible electroporation in the treatment of advanced pancreatic cancer. Eur J Surg Oncol. 2014;40:1598–1604. doi:10.1016/j.ejso.2014.08.480
   PubMed Web of Science ®Google Scholar
• Shinoto M, Terashima K, Suefuji H, et al. A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer. Radiother Oncol. 2018;129:333–339. doi:10.1016/j.radonc.2018.08.026
   PubMed Web of Science ®Google Scholar
• Yu EY, Petrylak DP, O’Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22:872–882. doi:10.1016/S1470-2045(21)00094-2
   PubMed Web of Science ®Google Scholar
• Thind K, Padrnos LJ, Ramanathan RK, Borad MJ. Immunotherapy in pancreatic cancer treatment: a new frontier. Therap Adv Gastroenterol. 2017;10:168–194. doi:10.1177/1756283X16667909
   PubMed Web of Science ®Google Scholar
• Pandit H, Hong YK, Li Y, et al. Evaluating the regulatory immunomodulation effect of Irreversible Electroporation (IRE) in pancreatic adenocarcinoma. Ann Surg Oncol. 2019;26:800–806. doi:10.1245/s10434-018-07144-3
   PubMed Web of Science ®Google Scholar
• Narayanan JSS, Ray P, Hayashi T, et al. Irreversible electroporation combined with checkpoint blockade and TLR7 stimulation induces antitumor immunity in a murine pancreatic cancer model. Cancer Immunol Res. 2019;7:1714–1726. doi:10.1158/2326-6066.CIR-19-0101
   PubMed Web of Science ®Google Scholar
• Li X, Huang Q, Hu X, et al. Evaluating the osteoimmunomodulatory properties of micro-arc oxidized titanium surface at two different biological stages using an optimized in vitro cell culture strategy. Mater Sci Eng C Mater Biol Appl. 2020;110:110722. doi:10.1016/j.msec.2020.110722
   PubMed Web of Science ®Google Scholar
• Lin M, Zhang X, Liang S, et al. Irreversible electroporation plus allogenic Vγ9Vδ2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients. Signal Transduct Target Ther. 2020;5:215. doi:10.1038/s41392-020-00260-1
   PubMed Web of Science ®Google Scholar